Dimethyl fumarate - Psoriasis
You are here : Home > Formulary Search > Dimethyl fumarate - Psoriasis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
- Not Specified
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Dimethyl fumarate
Indication :
Psoriasis
Group Name :
Keywords :
Biologic, immunosuppressant, fumaric acid ester, DMARD, bDmard, Disease modulating, Dermatology, biosimilar
Brand Names Include :
Skilarence
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Committee Recommendations (2)
The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed to adopt the SERMOG high-cost drugs pathway.for adiults with psoriasis
The PCN recommends Dimethyl Fumarate (Skilarence) as a treatment option for the treatment of moderate to severe Plaque Psoriasis in line with NICE TA475.
Prescribing will be by hospital specialists only, in line with NICE TA475 using Blueteq initiation and continuation forms. Dimethyl Fumarate (Skilarence) will be considered RED on the traffic light system.
Prescribing will be by hospital specialists only, in line with NICE TA475 using Blueteq initiation and continuation forms. Dimethyl Fumarate (Skilarence) will be considered RED on the traffic light system.
Other Indications
Below are listed other indications that Dimethyl fumarate is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Psoriasis.